Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Excluded: MS4A1 loss of expression

Must have received: systemic therapy — first-line

Patients who have failed first-line standard treatment (patients with relapsed disease < 12 months or primary refractory disease, or relapsed disease > 12 months but are transplant-ineligible after 1 line of systemic therapy, or relapsed disease after 2+ lines of therapy)

Cannot have received: bispecific antibody

Participants must not have received bispecific antibody therapy in the past

Cannot have received: anti-hematologic malignancy treatment

Participants have received anti-hematologic malignancy treatment within 2 weeks before the start of treatment or within 5 half-lives of the drug, whichever is longer

Cannot have received: large fraction radiation therapy

Exception: allowed if >4 weeks before first treatment and no radiation-related toxic reactions, no need for glucocorticoids, excluding radiation pneumonia, hepatitis, enteritis, etc.

Large fraction radiation therapy received within 4 weeks prior to the first treatment. For patients who received radiation therapy more than 4 weeks before the first treatment, all the following conditions must be met to be included: there are currently no radiation-related toxic reactions, no need to take glucocorticoids, excluding radiation pneumonia, radiation hepatitis, radiation enteritis, etc.

Cannot have received: traditional Chinese medicine with anti-tumor indications

Traditional Chinese medicine with anti-tumor indications received within 2 weeks before the first administration

Cannot have received: other clinical trial treatment

Treatment in another clinical trial within 4 weeks before the first administration